Jpmorgan Chase & CO Lucid Diagnostics Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 34 shares of LUCD stock, worth $27. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34
Previous 47
27.66%
Holding current value
$27
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding LUCD
# of Institutions
31Shares Held
2.15MCall Options Held
0Put Options Held
0-
Luminus Management LLC Houston, TX718KShares$588,4780.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA561KShares$459,9500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA156KShares$127,7200.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT150KShares$122,7520.01% of portfolio
-
Jane Street Group, LLC New York, NY122KShares$100,0500.0% of portfolio
About Lucid Diagnostics Inc.
- Ticker LUCD
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 38,568,500
- Market Cap $31.6M
- Description
- Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...